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Abstract
Background: The reverse transcriptase of telomerase (Tert) controls telomerase activity maintaining the end
of linear chromosomes in eukaryotic cells. Telomerase function is highly active in undifferentiated multipotent
stem cells, decreases with cell differentiation and is generally absent from most somatic cells in the adult. Its
absence is responsible of telomeres shortening in such somatic cells. Using an in vivo transgenic model and an in
vitro culture differentiation of adult stem cells, we examined the elements of the mouse Tert (mTert) promoter
that control telomerase activity.
Results: Three constructs comprising 1, 2 or 5 kb of the mTert promoter sequence coupled to the coding
sequence of the green fluorescent protein (EGFP) were electroporated into embryonic stem (ES) cells.
Transformed ES cells were able to mimic the expected mTert expression, which was associated to green
fluorescence. One and 5 kb promoter produced the higher expression of EGFP, on ES cells. When ES cells were
allowed to differentiate to embryoid bodies and to other cell types, they lost gradually the expression of mTert-
EGFP as consequence of differentiation. No differences were found among the three constructs analyzed. We
then generated transgenic mice with the three constructs. Expression of the reporter gene was monitored by
reverse transcription-PCR analysis and EGFP visualization. The mRNA expression of the three constructs was
lower than the endogenous mTert, but mimicked the endogenous mTert transcription pattern; however, no
fluorescent expression of EGFP was detected in adult tissues. EGFP expression of the three constructs was
visualized at the blastocysts stage and in new ES cells generated from them; in the germinal ring of E13 dpc
foetuses; in ES-like colonies and in germinal stem cells generated from neonatal and adult testis cells; and in
neuroesferes generated from E14 dpc foetuses' brain cells.
Conclusion: The 1 kb promoter upstream of the initiating ATG codon of mTert contains all the regulatory
elements to control telomerase expression in ES cells during in vitro loss of pluripotency. The transgenic mouse
lines generated represent an appropriate system to analyze the expression of mouse Tert gene under
physiological condition and during establishment of stem cell lines generated from embryonic or adult tissues.
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Background
Embryonic stem (ES) cells are undifferentiated cells that,
like somatic stem cells, possess the unique ability of self-
renewal and multilineage differentiation. ES cells are
derived from the inner cell mass of a developing pre-
implantation embryo. Unlike most somatic cells, ES cells
are spontaneously immortal and appear capable of indef-
inite self-renewal while retaining their ability to differen-
tiate and to contribute to the germ line after blastocyst
injection. The ability to self-renew indefinitely is lost as ES
cells differentiate to generate somatic tissue. One mecha-
nism that may underlie the capability of stem cells to rep-
licate indefinitely is the expression of the DNA repair
enzyme complex that includes telomerase, an RNA-
dependent DNA polymerase that maintains telomere
length [1]. Analysis of telomerase enzyme levels and activ-
ity has shown that high levels are expressed by ES cells [2]
while lower levels are expressed in proliferative cells of
renewal tissues. In addition, telomerase activity is down-
regulated in cells that exit the cell cycle via either terminal
differentiation or (reversible) quiescence. The key factor
that controls the activity of the telomerase is the reverse
transcriptase of telomerase (Tert) [2]. In contrast to most
somatic cells, stem, germ and tumour cells have high tel-
omerase activity through Tert transcriptional up-regula-
tion. One way of regulating telomerase activity appears to
be to regulate gene expression, and studies have begun to
identify key regulators. The human and mouse Tert pro-
moters were cloned in 1998 [3]. The core Tert promoter, a
region of 300 bp upstream of the transcriptional start site,
lacks a TATA sequence, but contains two E-boxes sur-
rounding several Sp1 binding sites. E-box sites bind sev-
eral cellular proteins, including the Myc/Mad/Max family
of transcription factors [3] (Fig. 1).
There are evidences that telomerase plays important roles
in the regulation of cell proliferation, differentiation, and
survival. Examples include how over expression of hTERT
can immortalize cultured fibroblasts and epithelial cells
[4]; the down-regulation of telomerase during muscle cell
differentiation [5]; and that Tert promotes cell survival
(prevents apoptosis) of developing mouse and rat brain
neurons [6]. High levels of Tert and telomerase activity
Promoter and regulators elements of the transcriptional of human and mouse TERT Figure 1
Promoter and regulators elements of the transcriptional of human and mouse TERT. CpG island in human and mouse TERT 
promoter identify using the CpG Island Explorer Program at http://www.bioinfo.hku.hk/cpgieintro.html are indicated in red line 
(A). Construct 5 k contain 4.5 Kb of the mouse promoter region, construct 1 k contains the proximal region of the promoter 
where all the transcription activator elements of the promoter reside (4 regions of c-Myc binding and two regions recognized 
by proteins from the sp1 family) and construct 2 k, includes, in addition to this proximal region, two of the three regions of 
MZF2 (myeloid zinc finger protein) binding, that reduces the transcriptional activity of the promoter (B).
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have been shown in several types of stem cells including
embryonic stem cells [7,8], hematopoietic stem cells [9],
and neural progenitor cells [10]. A progressive decrease in
telomerase levels appears to occur in association with suc-
cessive lineage restriction and cellular differentiation, sug-
gesting that telomerase could play an important role in
controlling cell fate and both human and mouse ES cells
maintain high telomerase activity [11,12]. Telomerase
activity is down-regulated during differentiation of rodent
and human ES cells [13,14] as well as in embryonal carci-
noma (EC) cells [15]. This suppression of telomerase
activity in differentiated EC cells requires histone
deacetylation in early hTERT gene down-regulation and
DNA methylation for maintenance of silencing of the
hTERT gene [15]. Both histone deacetylases (HDACs) and
methylation are tightly regulated in ES cells [16].
Current knowledge of Tert  regulation and telomerase
activity very largely derives from studies of neoplasic and/
or immortalised cell lines. Although useful for under-
standing cancer models, such studies may be less relevant
to normal stem cells and differentiation, and hence the
need to study telomerase regulation in normal develop-
ment. Recently it has been developed a transgenic mouse
model using the human TERT promoter to express bacte-
rial LacZ [17]. In two of the three transgenic lines gener-
ated LacZ expression was detectable only in testes, while
in the other line the pattern of expression was different
from the endogenous mouse Tert. We investigated the reg-
ulatory elements of the mice mTert promoter, using EGFP
as a live reporter of expression, to address a detailed anal-
ysis of this promoter activity under physiological condi-
tion in vivo and under stem cell generation. The aims of
this report were (i) to determine the region of the mTert
promoter that regulates telomerase activity during differ-
entiation of ES cells in vitro and in adult mice; (ii) to ana-
lyse the regulation of mTert during differentiation of ES
cells; (iii) to study the regulation of the mTert promoter in
an in vivo system; and (iv) to produce a reporter system
that identifies newly formed stem cell lines from embry-
onic, foetal, newborn, and adult tissues.
Materials and methods
Bioinformatics analysis
Homology searches were carried out using BLAST (Basic
Local Alignment Search Tool): http://
www.ncbi.nlm.nih.gov. The search for putative transcrip-
tion factor binding site was carried our using the Laser-
gene Sequence Analysis Software (DNASTART, Inc,
Wisconsin, USA). The CpG island was searched using the
CpG Island Explorer Program at http://www.bio
info.hku.hk/cpgieintro.html[18].
Generation of mTert-EGFP construct
Three constructs were generated using the available
sequence of 4471 bp of the promoter of mouse mTert gene
(NCBI Gene Banck; accession number AF 121949). Three
fragments of the mTert promoter of 1086, 1846, and 4471
bp, downstream of the first ATG of the open reading
frame of mTert gene, were amplified by PCR and ligated to
pEGFP (Clontech Laboratories, Inc., Palo Alto, CA, USA)
to promote the expression of EGFP. Orientation and
mTert promoter activity in R1 ES cells Figure 2
mTert promoter activity in R1 ES cells. On the left, the size of the mTert-pormoter-EGFP reporter construct is shown. Cells 
transformations with an EGFP plasmid without promoter are used as controls for each transfection. On the right, the relative 
GFP expression of the three promoter construct, and the standard deviation is indicated by solid bars. The GFP intensity pro-
duced by the promoterless construct was normalized to value of 100; GFP intensity of other constructs is shown relative to 
this control. Results are expressed as the mean of at least three independent experiments. A, b, c indicate p < 0.05 in a one-
tailed unpaired X2-test.
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sequence of each insert was checked by sequencing. The
constructs were named 1 k-, 2 k-, and 5 k-mTert-EGFP to
respectively indicate the construct with 1086, 1846 or
4471 bp of the mTert promoter. The plasmids were ampli-
fied and linearized before being used for electroporation
of ES cell.
Culture, transformation and differentiation of ES Cells
Undifferentiated mouse ES cells (R1 from A. Nagy lab.
and MAR1 a B6DF1 origin established by our group) were
maintained on mitomycin-C treated (Sigma-Aldrich cor-
poration St. Louis, MO, USA) mouse embryonic fibrob-
last (MEF) cells in 0.1% vol/vol gelatine coated tissue
plates in Dulbecco's modified Eagle medium (DMEM;
Invitrogen, Carlsbad, CA, USA) supplemented with 20%
FBS (PAA Laboratories Cölbe Germany), 2 mM
glutamine, 1 mM MEM nonessential amino acids solu-
tion, 1 mM β-mercaptoethanol, leukaemia Inhibitory Fac-
tor (LIF) 1000 U/ml and an antibiotic mixture containing
100 U/ml penicillin and 100 μg/ml Streptomycin (all
from Sigma-Aldrich).
Constructs 1 k-, 2 k- y 5 k-mTert-GFP were transfected by
electroporation in mouse stem cell lines R1 and MAR1 as
follow: ten micrograms of the linealized mTert-EGFP con-
struct were electroporated into 3 × 106 cells using a Multi-
porator (Eppendorf, Hamburg, Germany) and a pulse of
300 V, 500 μs. Cells were allowed to recover for 24 h
before G418 was added to a final concentration of 150 μg
/ml. Cellular clones were selected by geneticine resistance
over 7 days. At least ten clones of every construct were
taken up for further analysis. Clones were disaggregated
by trypsinization and allowed to attach on 96 well cell
culture cluster, maintained for 2 days in LIF (Leukemia
Inhibitory factor)-supplemented media until colonies
were formed. Then LIF was removed from the culture
media to allow the differentiation into embryoid bodies
(EBs) and different cellular types.
For the promoter assays, transient transfections of the
three transgenic constructs were performed into R1 ES
cells by electroporation as indicated above, and the GFP
activity of each construct was determined by flow cytom-
etry using FACSCalibur System and CellQuest software.
Cells transformed with an EGFP plasmid without pro-
moter were used as controls for each transfection. Three
independent experiments, each performed in duplicates,
were realized. The GFP mean fluorescence intensity was
expressed as relative intensity per positive cell with respect
to that of the promoterless construct, pEGFP.
Generation and screening of transgenic mice
Transgenic mice (C57BL6xCBAF1) generation and identi-
fication was carried out as previously described [19].
Briefly, transgene constructs (1 k-, 2 k, and 5 k-mTert-
EGFP) were released from the vector by restriction endo-
nuclease digestion and purified for embryo microinjec-
tion. Transgenic founders were backcrossed to
C57BL6xCBA mice to obtain homozygotic lines. PCR-
positive founder animals were confirmed by dot blot
analysis and both the integrity and the transgene trans-
mission were analysed during two generations. All the
animals were maintained in an animal facility using pro-
cedures and protocols that are approved by our Institu-
tional Animal Care and Use Committee.
Analysis of GFP mRNA expression in different tissues of 
transgenic mice by RT-PCR
Poly (A+) RNA was extracted from liver, spleen, kidney,
heart, testis, ovary, and brain of transgenic mice at differ-
ent ages using the Ultraspect™ RNA Isolation System fol-
lowing the manufacturer's instructions (Biotecx Lab. Inc.,
Houston, Texas, USA). The precipitated mRNA was dis-
solved in DEPC-treated water and then treated with 1 U of
RQ DNAse I (Promega) at 37°C for 20 min to ensure that
the only source of DNA in the polymerase chain reaction
(PCR) was cDNA from cellular RNA. Finally, the RNA was
extracted with phenol purification and ethanol precipita-
tion, reconstituted in 50 μl of DEPC-treated water and
stored at -70°C until the RT-PCR.
The RT reaction was carried out following the manufac-
turer's instructions of Epicentre (Tech. Corp., Madison,
Wisconsin). Five micrograms of poly(A+)RNA were dis-
solved in water, heat-denatured (65°C, 2 min) and
reverse-transcribed at 37°C for 60 min in a final volume
of 25 μl containing 0.5 mM each dNTP, 0.2 μM oligo (dT),
MMLV-RT (0.5 μl), RNAsin (0.2 μl), 1× MMLV-RT buffer
and 8 mM DTT. After reverse transcription, PCR was per-
formed adding 5 μl aliquot of each sample to the PCR mix
containing the specific forward primers GFP-1 (5'-TGA
ACC GCA TCG AGC TGA AGG G-3') and GFP-2 (5'-TCC
AGC AGG ACC ATG TGA TCG C-3'), which specifically
amplified a 340 bp GFP DNA. For mice Tert amplification,
primers and length of the PCR product were mTert-F1 (5'-
ACT TCA ACC GCA AGA CCG ACA GG-3') and mTert-R2
(5'-GGG TGG CCA TCA GTC CAG GAT GG-3') (451 bp).
Amplification was carried out in a total volume of 25 μl
(1× of PCR mix containing 1 u Taq polymerase, 2.5 μl 10×
buffer, both from Promega, 100 μM each dNTP, 0.1 μM
each primer and 2.5 mM MgCl2) Samples were loaded
directly from ice into the heating block at 92°C to mini-
mize the time required to reach denaturation tempera-
tures. For semi-quantification of the mRNA, the amount
of cDNA in all of the samples was equalized. In order to
determine the lowest PCR cycle number that gave a relia-
ble detectable product, a linear range of amplification was
previously set. Amplification was done with an initial step
of 92°C (2 min), followed by 23 cycles for β-actine and
GFP, and 26 for mTert of 92°C (30 sec), 59°C (30 sec)Reproductive Biology and Endocrinology 2006, 4:5 http://www.rbej.com/content/4/1/5
Page 5 of 12
(page number not for citation purposes)
and 72°C (30 sec). The final cycle extension was at 72°C
(10 min). PCR products were resolved in 1.5% TBE agar-
ose gels, followed by staining with ethidium bromide,
and visualized using UV light. The relative abundance of
each PCR product was determined by quantitative analy-
sis of digital photographs of gels using the plug-in of
Image Processing Tool Kit 5.0 (Reindeer Games Inc.,
Asheville, NC, USA). Negative control experiments in the
absence of template RNA were performed. Generation of
the expected fragments was strictly dependent on the pres-
ence of RNA in the RT reaction, as demonstrated with β-
actine amplification, as a non-competitive internal stand-
ard control of the RT-PCR. To minimize variability, dupli-
cate runs were performed for each mRNA amplified and
the data were averaged.
Immunohistochemistry
Ten- to twenty-micrometer cryosections were blocked
with 5% goat serum in TBST (Tris 0.1 M, NaCl 150 mM,
pH 7.5, Triton 0.1% vol/vol blocking solution), then
incubated for 1 hour at room temperature (r.t.) with anti-
GFP rabbit polyclonal antibodies (1:600. Molecular P
robes, Eugene, OR. USA) diluted in TBST 5% goat serum.
Sections then were washed three times with TBS (Tris 0.1
M, NaCl 150 mM, pH 7.5) and incubated with highly
cross-adsorbed Alexa 488 anti-rabbit secondary antibod-
ies (1:500. Molecular Probes) for 1 hour at r.t. Finally, sec-
tions were counterstained with Hoechst 33342
(Molecular Probes), and mounted with Aqua Polymount
mounting media (Poly-Labo).
Analysis of transgene expression in pluripotent stem cell 
isolated from testis of transgenic mice
ES-like colonies and germinal stem cells were obtained
from neonatal and adult testis cells which were collected
from a newborn transgenic 1 k-mTert-GFP mouse line of
C57BL6/CBA F1 background (0–3 days old) and from
21–28 days old mice. Testis cell culture was performed
according to the previously published protocol [20] with
slight modifications. Briefly, testis cells were digested with
1 mg/ml collagenase (type IV, Sigma-Aldrich corporation
St. Louis, MO, USA) for 10 min at 37°C, followed by
0.05% vol/vol trypsin/0,1 mM EDTA digestion for 3 min
at 37°C. Testis cells were allocated to a tissue culture plate.
2.5 hours later, floating cells were recovered and passed to
secondary culture plates on mitomycin-C treated (Sigma-
Aldrich) mouse embryonic fibroblast (MEF) cell in 0.1%
vol/vol gelatine coated tissue plates in Dulbecco's modi-
fied Eagle medium (DMEM; Invitrogen, Carlsbad, CA,
USA) supplemented with 20% FBS (PAA Laboratories
Cölbe Germany), 2 mM glutamine, 1 mM MEM nones-
sential amino acids solution, 1 mM β-mercaptoethanol,
leukaemia Inhibitory Factor (LIF) 1000 U/ml and an anti-
biotic mixture containing 100 U/ml penicillin and 100
μg/ml Streptomycin 20 ng/ml mouse epidermal growth
factor, 10 ng/ml human basic fibroblast growth factor, 10
ng/ml recombinant rat glial cell line-derived neurotrophic
factor (GDNF) (all from Sigma-Aldrich).
Analysis of transgene expression in neuroesferes obtained 
from E14 foetus brain of transgenic mice
Fore brain of E14 foetus of 1 k-, 2 k, and 5 k-mTert-EGFP
transgenic mice were dissected and cut in small pieces.
The tissue was suspended in HBSS (Sigma) with DNAsa
0.005% wt/vol (Sigma) and Papain 20 U/ml (Roche).
Digestion was carried out at 37°C with gentle agitation
every five minutes during 15 minutes. Digested tissue was
centrifuged and pellet was suspended in DNAsa HBSS and
mechanically dissociated with decreasing fire polished
Pasteur pipettes. Cells were centrifuged twice with DNAsa
HBSS and pellet was suspended in DMDM:F12, N2 sup-
plements, AANE, Hepes 10 mM, Glucose 6 g/l, Albumax
0.1% vol/vol counted and seed at 400.000 cells/ml in the
same medium plus 20 ng/ml of FGF (AbCys) and 20 ng/
ml of EGF (AbCys). Neurospheres were mechanically trit-
urated and diluted 1/5 weekly.
Results
Analysis of nucleotide sequence of human and mouse 
TERT promoter
To investigate the relationship between mouse and
human TERT promoter, homology comparison was car-
ried out between 4489 pb of the mTert (AF121949) and
3996 bp of hTERT (AF097365) sequences (Fig. 1). We
have analyzed the presence of the transcription factor
binding sites (SP1, c-Myc, Zap3 and MZF2), and the pres-
ence of CpG motif (Fig. 1). No significant sequence iden-
tity could be identified except for the 55 pb immediately
upstream of the ATG, and another 500 bp located from
position -1.4 in mouse and -1.6 in human sequences (Fig.
1). The human and mice TERT sequences have a core pro-
moter of 220 bp with three putative SP1 and two c-Myc.
The mouse promoter has another 2 c-Myc in the first -1 kb
upstream of the ATG and does not have any more SP1,
meanwhile the human promoter presents 7 SP1 located
along the promoter. Another difference is that the human
promoter has 4 inhibitors MZF2 located between -0.5 and
-0.8 kb, and mouse promoter has three MZF2 located
between -1.8 and -2.5 kb. Moreover, only the Zap3 bind-
ing site present in the core promoter closer to the initiat-
ing AUG codon, is conserved between human and mouse
promoters.
The analysis of CpG islands showed a different pattern
between hTERT and mTert promoters. The human pro-
moter has three CpG islands covering in total more that
1.6 kb in length meanwhile in the mouse promoter a sin-
gle CpG island covers 0.4 kb in length (Fig. 1).Reproductive Biology and Endocrinology 2006, 4:5 http://www.rbej.com/content/4/1/5
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ES cell differentiation modifies mTert expression
To identify relevant elements for the regulation of mTERT
we designed three constructs (detailed in the Fig. 1) with
different promoter regions. The 1 k-mTert-GFP contains
the proximal region of the promoter where all the tran-
scription activator elements of the promoter reside (2
regions of c-Myc binding, 2 regions of Zap3 binding, and
3 regions recognized by proteins from the sp1 family).
This promoter also contains the single CpG island of the
4.5 kb promoter (Fig. 1). Construct 2 k, includes, in addi-
tion to this proximal region, two of the three regions of
MZF2 (myeloid zinc finger protein) binding, that reduces
the transcriptional activity of the promoter. Construct 5 k
contains 4.5 Kb of the mouse promoter region.
To analyze the promoter activity of the 5' flanking mTert
region, the three transgenic constructs were transiently
transfected into R1 ES cells, and the GFP activity of each
construct was determined by flow cytometry. More than
twofold significant increase in GFP activity was found in
cells transfected with the three mTert promoter constructs.
The shorter and the longer constructs showed better tran-
scriptional activity compared to the 2-kb promoter (Fig
2).
To analyze the regulation of mTert-EGFP during ES cell
differentiation, we produced mTert-EGFP marked cell
lines by stably transfecting these three constructs into
murine ES cells (R1 and MAR1). The ES cell in presence of
LIF expressed EGFP but only 3 days after removal of LIF,
the ES cells were transformed into embryoid bodies (EBs)
(Fig 3). During this process EGFP expression increased
(Fig 4). In the next step of the differentiation process,
where EBs evolved into differentiated cells, EGFP expres-
sion was lost. However, in some wells, groups of EGFP
expressing cells remained immersed into differentiated
colonies, even 9 days after LIF removal (Fig. 3). No differ-
ences were observed between the 3 constructs.
To analyze the possible differences between ES cell lines,
we transformed 5 k-mTert-GFP in two ES cell lines (R1 and
MAR1). Similar GFP expression levels were observed in
the different 5 k-mTert-GFP cellular clones derived from
B6D2 (76 clones) or R1 (85 clones) ES cell lines (Fig. 4).
Establishment of transgenic mice lines and expression of 
EGFP in transgenic tissues
Eight lines of transgenic mice carrying the 1 k-mTert-EGFP
transgene, 3 carrying the 2 k-mTert-EGFP transgene and 5
Sequence of microphotograph of ES cells transformed with 5 k-mTert-EGFP during differentiation induced by LIF removal Figure 3
Sequence of microphotograph of ES cells transformed with 5 k-mTert-EGFP during differentiation induced by LIF removal. (A) 
ES cell expressing EGFP; (B) three days after LIF removal the ES cells form embryonic bodies (EBs); (C) Differentiation of EBs 
showing a diminishes on fluorescence intensity; and (D) next stage of differentiation showing a loss of fluorescence; in some 
wells groups of EGFP expressing cells remain immersed into differentiated colonies.
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Levels of GFP expression (none, low, medium or high) in the different 5 k-mTert-GFP cellular clones derived from B6D2 and  R1 ES cell lines Figure 4
Levels of GFP expression (none, low, medium or high) in the different 5 k-mTert-GFP cellular clones derived from B6D2 and 
R1 ES cell lines. (A) 5 kmTert-GFP expression in 76 B6D2 clones, and (B) 5 kmTert-GFP expression in 85 R1 clones. GFP 
expression increased during 2–3 d after removal of LIF and subsequently diminished in parallel to EBs differentiation.
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Expression of 1 k-mTert-EGFP transgene at blastocyst stage (A, B) and ES-like colonies (C, D) and germinal stem cells (E, F)  generated from neonatal testis cells Figure 5
Expression of 1 k-mTert-EGFP transgene at blastocyst stage (A, B) and ES-like colonies (C, D) and germinal stem cells (E, F) 
generated from neonatal testis cells.
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carrying the 5 k-mTert-EGFP transgene were obtained. We
first analyzed the EGFP expression at the blastocyst stage
under fluorescent microscopy, finding similar levels of
expression in all the lines (Fig 5A–B). Then, we analyzed
EGFP expression during foetal development using inmu-
nocytochemistry from E8 to E19 dpc embryos. Only some
Table 1: mTert-EGFP transgene expression in different tissues
1 K mTert-EGFP 2 K mTert-EGFP 5 K mTert-EGFP Mouse Tert
Tissue 4 15 3 5 7 50
Liver ++ + + - + + +++
S p l e e n + + +++++ + + +
Kidney + - - + - + +
Heart + - - - + - +
Testis ++ ++ ++ + + ++ ++++
Ovary ++ + ++ + + + ++
Brain + - + - + - +
-, No expression; +, relatively low level of expression; ++. Moderate expression; +++, high level of expression.
Fluorescence and contrast phase images of 10DIV cultures of forebrain foetus from 1 k-mTert-EGFP (A) and 5 k-mTert-EGFP  (B) transgenic mice Figure 6
Fluorescence and contrast phase images of 10DIV cultures of forebrain foetus from 1 k-mTert-EGFP (A) and 5 k-mTert-EGFP 
(B) transgenic mice.Reproductive Biology and Endocrinology 2006, 4:5 http://www.rbej.com/content/4/1/5
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lines showed a weak fluorescence in E13 dpc embryos in
the germinal ring. No expression was detected in other tis-
sues. For the rest of the experiments, two lines of each con-
struct were selected based on two criteria, first that the
transgene were integrated into an autosomal chromo-
some and could be transmitted stably with a transgene
transmission ratio of 50%, and second that EGFP expres-
sion at the blastocyst stage and in E13 germinal ring were
detectable (Table 1). We then examined EGFP mRNA
expression in liver, spleen, kidney, heart, testis, ovary and
brain of the 6 transgenic lines selected (Table 1). The
mRNA expression of the three construct was lower than
the endogenous mTert, but it recapitulated the endog-
enous mTert transcription pattern.
We then analyzed the fluorescent emission of endogenous
EGFP under fluorescent microscopy and expression of
EGFP protein using specific antibodies (see Material and
Methods) of different tissues (bone marrow, liver, spleen,
kidney, heart, testis, ovary and brain) of neonates and
adult mice. No endogenous fluorescent expression of GFP
was detected in any tissue. Expression of EGFP protein
was also undetectable during foetal development with
anti-GFP antibodies, corroborating the low levels of RNA
found by RT-PCR studies.
Expression of EGFP in cultured cells generated from 
transgenic embryos or tissues
We then analyzed if our three constructs could express
detectable amounts of GFP (to be detectable under con-
ventional fluorescent microscopy) in populations of stem
cells generated and expanded in vitro from embryonic,
foetal, or adult transgenic tissues. The fluorescent expres-
sion of EGFP driven by the three constructs was visualized
at the blastocyst stage (Fig. 5A–B) and new ES cells lines
generated from them (Fig. 5C–D); also it was visualized in
ES-like colonies and germinal stem cells generated from
neonatal and adult testis cells (Fig. 5 E–F).
Fluorescence was detectable in cultures generated from
E14 foetus brain cells derived from 1 k-mTert-EGFP (Fig
6A) and 5 k-mTert-EGFP mice (Fig 6B). In both cases it
could be visualized at least until 10DIV (Fig 6). FACs anal-
ysis at 48 h after seeding showed a more intensive fluores-
cence in 5 k-mTert-EGFP cells compared to those of 1 k-
mTert-EGFP origin (data not shown).
Discussion
While there is much information about the human TERT
promoter, little work has been carried out with mTert pro-
moter [2,21,22]. Our results indicate that there are consid-
erable differences between mTert and hTERT promoters,
and that, at least in ES cells, the regulation of the transcrip-
tional activity of the mTert promoter, in contrast with its
human homologue, resides primarily in the proximal
region. The differences between the two species may in
fact aid our understanding of the function for telomerase
regulation.
The differences in CpG islands may indicate a higher reg-
ulation of hTERT  by methylation. It has been demon-
strated that the epigenetic regulation of hTERT  during
differentiation is meditated by histone acetylation and
cytosines methylation in the TERT promoter. The differ-
ences between human and mice Tert promoters may indi-
cate the differences in regulation of these genes between
both species. This could explain in part the differences in
senescence and immortalisation between human and
mouse primary culture cells. If the regulation of mTert
expression represents a key gatekeeper for the transition to
an immortal phenotype in the mouse, as it appears to be
for human cells, then the continued expression of Tert in
mouse cells and tissues could be an important permissive
factor enabling their cancer-prone phenotype. It has been
proposed that telomerase length is differently regulated in
both species [23]. Another difference is the presence of
Sp1 binding sites. mTert only has 2 sites very proximal to
the ATG, whereas hTERT has at least 9 Sp1 binding sites
dispersed along the 4 kb promoter. The clustering of Sp1
sites is a common event in promoters of TATA-less genes
[24]. It is becoming increasingly clear that full transcrip-
tional activity of the hTERT promoter requires the SP1
transcription factor [25,26]. There are also differences
between Ap-1 sites. Recently it has been demonstrated
that the species-specific function of Ap-1 in TERT expres-
sion may explain in part, the difference in transcriptional
suppression of telomerase activity between normal
human and mouse somatic cells [27].
One common thing between both promoters is the pres-
ence of c-Myc binding sites. It has been previously
reported the presence of c-Myc and Sp1 binding sites in
hTERT [28], and it has been also shown that c-Myc acti-
vates telomerase, an effect attributed to direct interaction
of c-Myc with the hTERT promoter [29]. mTert promoter
contains only some conserved regions compared to
hTERT promoter, in particular the c-Myc binding region
[21], suggesting that activation of telomerase by c-Myc
could be a general mechanism conserved among mice and
man. Only one Zap3 binding site is conserved between
human and mouse promoters, suggesting that this site
may be potentially significant in the regulation of Tert
promoter activity. Recently it has been suggested that
Zap3 binding sites play a role in controlling the absolute
levels of mTert  transcription [30]. The other common
binding motif identified is the MZF (myeloid zinc finger
protein 2). Deletion analysis of hTERT has shown that
these motifs are in a negative regulatory region [31]. In
addition, the over-expression of MZF2 in 2 human cell
lines led to the down-regulation of transcriptional activi-Reproductive Biology and Endocrinology 2006, 4:5 http://www.rbej.com/content/4/1/5
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ties of hTERT promoter, indicating that MZF binding sites
may act as negative regulatory elements and regulate the
expression of hTERT [31]. In humans, this region has been
named as intermediate promoter region and it has been
determined that it strongly reduced hTERT  promoter
activity [32]. mTert promoter has three binding sites for
MZF2, we have found also an effect of the presence of the
region containing these elements on the expression of our
construct, indicating a similar function of this repressor
binding sites between species. Our results agree with Arm-
strong et al. [30] and confirm that the principal transcrip-
tional regulation sites are present in the 1 k-mTert
promoter.
The regulation of the transcriptional activity in ES cells of
the mTert promoter, in contrast with its human homolog,
resides primarily in the proximal region to the coding
region. The sequence divergence between the human and
mouse telomerase RNA gene promoter regions may
explain the differences in telomerase regulation between
human and mice species. Because the final function of the
telomerase in both species is the same, the differences
between the two promoters may in fact aid our under-
standing of the function for telomerase regulation.
During the process of differentiation no differences were
observed between the 3 constructs, indicating that the 1 k
promoter contains all the necessary elements for the cor-
rect regulation of mTert expression in ES cells. The increase
in the expression of EGFP we observed during the forma-
tion of EBs could be a consequence of the enhanced cell
proliferation at this period. After EBs stage, the expression
of EGFP decreases during the process of differentiation,
suggesting that there is a close correlation between the
down-regulation of mTert and the differentiation process.
Similar results have been reported by [2] during haemat-
opoietic differentiation of ES cells. Using a construct with
a similar 4.5 kb mTert, they found that those cells express-
ing high levels of transgenic construct also showed a sig-
nificant telomerase activity. We have found here that only
the first 1 kb of the promoter is necessary to induce the
same phenotype. In vivo experiments confirmed this sim-
ilar pattern, equivalent expression levels were found
among transgenic lines produced with the 1 K, 2 K or 5 K
promoter.
In our transgenic model no fluorescent expression of the
mTert-EGFP construct could be identified in adult tissues.
This suggests either a scarce presence of adult stem cells in
the total population of adult tissues, with undetectable
expression levels in physiological conditions, or a tight
repression system of this promoter. A similar effect was
observed [2,17] using hTERT promoter. However, when
tumours were induced in their transgenic models, expres-
sion levels became detectable. In our case we were able to
recover expression levels when new stem cell lines were
established from embryonic, foetal, newborn and adult
tissues obtained from transgenic animals of all the lines
selected. This suggests that the construct was functional
and that its activity in adult tissues migth not be a conse-
quence of transgene inactivation but a consequence of the
mechanism of telomerase physiological repression in the
adult tissue. mTert activity is recovered when repression
mechanisms disappear as a consequence of in vitro culture
conditions that stimulates cell proliferation and undiffer-
enciation like those used for stem cell generation. This up-
regulation of Tert activity observed in our new stem cell
originated under in vitro culture conditions and the up-
regulation observed in tumours are indicating that Tert
expression is related with a transformation stage of the
cells that confers a survival advantage.
Conclusion
mTert-EGFP system is an excellent marker for the identifi-
cation of the promoter elements that regulate mTert activ-
ity during stem cell differentiation
The 1 kb promoter upstream of the initiating ATG codon
contains all the regulatory elements to regulate telomerase
expression in ES cells during in vitro loss of pluripotencia.
The regulation of the transcriptional activity in ES cells of
the mTert promoter, in contrast with its human homolog,
resides primarily in this proximal region of the coding
region. The sequence divergence between the human and
mouse telomerase RNA gene promoter regions may
explain the differences in telomerase regulation between
human and mice species
This transgenic mouse model generated is a potential
reporter system for the selection and isolation of stem
cells generated from embryos (ES cells), from foetus (neu-
roesferes) and from newborn tissues (ES-like and germi-
nal stem cells).
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